Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.

IF 2 4区医学 Q3 HEMATOLOGY

Hematology Pub Date : 2024-12-01 Epub Date: 2024-04-26 DOI:10.1080/16078454.2024.2344998

Ziyi Hao, Yingying Fei, Juan Chen, Sailan Huang, Li Wang, Youhuan Yu, Meiru Bian, Yejun Si, Xingxia Zhang, Xiaotian Yang, Bing Zhang, Yan Wan, Yanming Zhang, Guoqiang Lin

{"title":"Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.","authors":"Ziyi Hao, Yingying Fei, Juan Chen, Sailan Huang, Li Wang, Youhuan Yu, Meiru Bian, Yejun Si, Xingxia Zhang, Xiaotian Yang, Bing Zhang, Yan Wan, Yanming Zhang, Guoqiang Lin","doi":"10.1080/16078454.2024.2344998","DOIUrl":null,"url":null,"abstract":"Objectives: Relapsed/refractory acute B-cell lymphoblastic leukemia (R/R B-ALL) often responds poorly to induction chemotherapy. However, recent research has shown a novel and effective drug treatment for R/R B-ALL.Methods: A total of eight patients with R/R B-ALL were enrolled in the study from November 2021 to August 2022. All patients received chemotherapy based on a combination regimen of venetoclax and azacitidine. The regimen was as follows venetoclax 100 mg d1, 200 mg d2, 400 mg d3-14, azacitidine 75 mg/m2 d1-7.Results: Five of eight patients achieved very deep and complete remission (CR) with minimal residual disease (MRD) less than 0.1%. One patient achieved partial remission. Two patients did not achieve remission. There were no serious adverse events and all patients were well tolerated. Three patients were eligible for consolidation chemotherapy and were bridged to CAR-T therapy.Conclusions: The combined regimen of venetoclax and azacitidine may be beneficial for patients with R/R B-ALL.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"29 1","pages":"2344998"},"PeriodicalIF":2.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/16078454.2024.2344998","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Relapsed/refractory acute B-cell lymphoblastic leukemia (R/R B-ALL) often responds poorly to induction chemotherapy. However, recent research has shown a novel and effective drug treatment for R/R B-ALL.

Methods: A total of eight patients with R/R B-ALL were enrolled in the study from November 2021 to August 2022. All patients received chemotherapy based on a combination regimen of venetoclax and azacitidine. The regimen was as follows venetoclax 100 mg d₁, 200 mg d₂, 400 mg d_3-14, azacitidine 75 mg/m² d_1-7.

Results: Five of eight patients achieved very deep and complete remission (CR) with minimal residual disease (MRD) less than 0.1%. One patient achieved partial remission. Two patients did not achieve remission. There were no serious adverse events and all patients were well tolerated. Three patients were eligible for consolidation chemotherapy and were bridged to CAR-T therapy.

Conclusions: The combined regimen of venetoclax and azacitidine may be beneficial for patients with R/R B-ALL.

查看原文本刊更多论文

复发/难治性急性B细胞淋巴细胞白血病患者联合使用venetoclax和阿扎胞苷：来自单一中心的病例系列。

研究目的复发/难治性急性B细胞淋巴细胞白血病（R/R B-ALL）通常对诱导化疗反应不佳。然而，最近的研究显示了一种治疗 R/R B-ALL 的新型有效药物：方法：2021年11月至2022年8月，共有8名R/R B-ALL患者被纳入研究。所有患者均接受了基于文尼他克（venetoclax）和阿扎胞苷联合方案的化疗。方案如下 Venetoclax 100 mg d1、200 mg d2、400 mg d3-14，阿扎胞苷 75 mg/m2 d1-7：结果：8名患者中有5名获得深度完全缓解（CR），最小残留病灶（MRD）小于0.1%。一名患者获得部分缓解。两名患者未达到缓解。所有患者均无严重不良反应，耐受性良好。三名患者符合巩固化疗的条件，并接受了CAR-T疗法：结论：venetoclax和阿扎胞苷联合方案可能对R/R B-ALL患者有益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology 医学-血液学

CiteScore

2.60

自引率

5.30%

发文量

140

审稿时长

3 months

期刊介绍： Hematology is an international journal publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology. Of the fixed sections, annotations are accepted on any general or scientific field: technical annotations covering current laboratory practice in general hematology, blood transfusion and clinical trials, and current clinical practice reviews the consensus driven areas of care and management.